Professional Documents
Culture Documents
20
10 2010
Hagen Kennecke, Rinat Yerushalmi, Ryan Woods, Maggie Chon U. Cheang, David Voduc,
Caroline H. Speers, Torsten O. Nielsen, Karen Gelmon
British Columbia Cancer Agency; Genetic
Pathology Evaluation Centre, University
of British Columbia, Vancouver, British
Columbia, Canada; and the Lineberger
Comprehensive Cancer Center, University
of North Carolina at Chapel Hill, Chapel
Hill, NC.
2 2009 .;
8 2010 .;
24 2010 . :
www.jco.org.
Canadian
Breast Cancer Foundation, British Colubia-Yukon Division. Genetic
Pathology Evaluation Centre
sanofi-aventis (),
Michael Smith Foundation for
Health Research.
.
Hagen Kennecke, MD,
MHA, FRCPC, Vancouver Clinic, Division
of Medical Oncology, British Columbia
Cancer Agency, 600 West 10th Ave,
Vancouver, British Columbia, V5Z 4E6,
Canada; e-mail: hkennecke@bccancer.
bc.ca.
2010 by American Society of Clinical
Oncology
()
; , , .
, 19861992 .,
.
: , , 2 (HER2-), HER2, , . : , , ,
, , / . .
, .
3726 14,8 .
2,2 ( ), 1,6 ( ), 1,3 ( HER2+), 0,7 (HER2+) 0,5 () (p < 0,001). ,
, . ,
, HER2+, HER2+ , .
, , .
, .
0732-183X/10/2820-3271/$20.00
DOI: 10.1200/JCO.2009.25.9820
.
J Clin Oncol 28:3271-3277. 2010 by American Society of Clinical Oncology
,
2030 % ()
.1 .
, ,
,
, 2 2
(HER2).3 .
() (-), -
, , ,
, 4 -.5 .6
,
. , ,7-12
HER2
.2,13-22
,23 24,25 .26-28
Downloaded from jco.ascopubs.org on April 28, 2014. For personal use only. No other uses without permission.
Copyright 2010 American Society of Clinical Oncology. All rights reserved.
271
Kennecke et al.
Agency, . Estrogen
Receptor Tissue Bank 4543 ; 146 (3,2 %) - (1). 671
(0) -
. 3726 .
( ).29,30 ( -
) (), (), HER2,
Ki-67, (EGFR) () 5/6.26,28 - -
(, 1 %), HER2 3+; 2+
in situ ( 2,0).
, 50 , .
, .
, .
15-
: , , HER2+, HER2+ ; - ,
.
1. 3726
A (n = 1639)
a
T02
T34
Na
N0
N1
N2N3
62
5171
B (n = 893)
.
60
4770
HER2+ (n = 243)
.
58
4868
HER2+
(n = 266)
.
(n = 367)
56
4665
53
4265
(n = 318)
.
56
4567
< 0,001
379
43
23,1
2,6
284
27
31,8
3,0
73
11
30,0
4,5
92
4
34,6
1,5
148
13
40,3
3,5
104
11
32,7
3,5
< 0,001
1416
66
157
86,4
4,0
9,6
741
45
107
83,0
5,0
12,0
196
20
27
80,7
8,2
11,1
214
21
31
80,5
7,9
11,7
299
22
46
81,5
6,0
12,5
251
25
42
78,9
7,9
13,2
0,0019
909
631
19
55,5
38,5
1,2
446
375
24
49,9
42,0
2,7
102
120
9
42,0
49,4
3,7
114
129
5
42,9
48,5
1,9
218
123
4
59,4
33,5
1,1
179
115
8
56,3
36,2
2,5
< 0,001
80
4,9
48
5,4
12
4,9
18
6,8
22
6,0
16
5,0
618
86
37,7
5,2
440
46
49,3
5,2
146
6
60,1
2,5
141
8
53,0
3,0
147
20
40,1
5,4
128
17
40,3
5,3
< 0,001
970
549
120
59,2
33,5
7,3
364
490
39
40,8
54,9
4,4
71
162
10
29,2
66,7
4,1
56
203
7
21,1
76,3
2,6
41
317
9
11,2
86,4
2,5
100
199
19
31,4
62,6
6,0
< 0,001
1489
150
90,8
9,2
826
67
92,5
7,5
237
6
97,5
2,5
259
7
97,4
2,6
334
33
91,0
9,0
274
44
86,2
13,8
< 0,001
243
1190
206
922
14,8
72,6
12,6
56,3
132
651
110
566
14,8
72,9
12,3
63,4
51
169
23
162
21,0
69,5
9,5
66,7
42
195
29
116
15,8
73,3
10,9
43,6
44
267
56
118
12,0
72,8
15,3
32,2
47
231
40
143
14,8
72,6
12,6
45,0
0,1699
< 0,001
392
23,9
329
36,8
104
42,8
142
53,4
176
48,0
129
40,6
< 0,001
25
888
726
1,5
54,2
44,3
14
510
369
1,6
57,1
41,3
2
160
81
0,8
65,8
33,3
3
162
101
1,1
60,9
38,0
7
200
160
1,9
54,5
43,6
6
173
139
1,9
54,4
43,7
12
3
/
b
, c
95%
10- , %c
95%
2,2
1,92,5
70
67,872,3
1,6
1,41,8
54,4
51,257,7
1,3
1,11,7
46,1
39,852,4
0,7
0,60,8
48,1
42,154,1
0,5
0,40,7
52,6
47,557,7
0,9
0,71,1
62,6
57,367,9
0,0127
< 0,001
< 0,001
. 2; .
: ; ; .
a
American Joint Committee on Cancer, 6- , 2002.
b
, , ; .
c
- .
272
3726 , 44 % , 24 % , 6,5 %
HER2+, 7,1 % HER2+, 9,8 % 8,5 % .
14,8 . , . 1.
,
HER2+ (p < 0,001). 4259 %
,
(59 %). (
) 3- , www.jco.org
1,0
0,8
0,6
A
B
HER2+
HER2+
0,4
0,2
p<0,001
10
15
,
. 1.
Downloaded from jco.ascopubs.org on April 28, 2014. For personal use only. No other uses without permission.
Copyright 2010 American Society of Clinical Oncology. All rights reserved.
273
Kennecke et al.
2. 15-
,
%
95% ,
%
1639
2,2
1,63,0
7,9
6,79,4
6,7
5,57,9
18,7
16,820,7
4,5
3,55,6
7,8
6,69,2
3,8
2,94,8
893
4,7
3,46,2
13,8
11,616,2
13,4
11,215,8
30,4
27,433,5
9,6
7,811,7
14,7
12,517,2
8,1
6,410,0
HER2+, +, +
244
7,9
4,812,0
21,3
16,326,7
17,7
13,222,8
30,9
25,236,7
10,5
7,014,8
16,0
11,721,0
6,6
3,910,2
HER2+, ,
266
14,3
10,418,8
23,3
18,428,6
24,1
19,129,3
30,1
24,735,7
13,0
9,217,4
16,2
12,020,9
8,8
5,812,7
367
10,9
8,014,3
9,3
6,612,5
18,5
14,722,7
16,6
13,020,6
17,2
13,521,2
12,8
9,616,5
10,4
7,513,7
318
7,2
4,710,4
10,7
7,614,4
12,5
9,116,5
15,1
11,419,4
12,3
8,916,1
9,2
6,312,7
9,2
< 0,001
< 0,001
,
%
< 0,001
95% , , 95% ,
%
%
%
< 0,001
,
%
< 0,001
95% ,
%
, 95% , , 95% ,
%
%
%
%
< 0,001
,
%
95% ,
%
6,212,9
< 0,001
. p , .
,
- / ,
, HER2+, ( 0,6; 95% 0,40,9)
( 1,8; 95% 1,03,0; .
. 1 , ).
,
. ,
.
, - .
, .
,
;
. , 5667 %
; . 1,32
HER2- .33,34 3753 % .
,
, ,
3.
458
35
7,6
131
28,6
109
23,8
305
66,6
73
15,9
129
28,2
62
13,5
36
7,9
378
41
10,8
121
32,0
115
30,4
270
71,4
88
23,3
133
35,2
73
19,3
13
3,4
HER2+, +, +
117
18
15,4
52
44,4
43
36,8
76
65,0
26
22,2
40
34,2
16
13,7
5,1
HER2+, ,
136
39
28,7
62
45,6
64
47,1
81
59,6
34
25,0
43
31,6
23
16,9
4,4
159
40
25,2
34
21,4
68
42,8
62
39,0
63
39,6
47
29,6
38
23,9
11
6,9
109
24
22,0
35
32,1
39
35,8
47
43,1
39
35,8
31
28,4
28
25,7
5,5
< 0,001
< 0,001
< 0,001
< 0,001
< 0,001
0,3214
0,0056
0,1338
. p 2.
274
4.
95%
95%
95%
95%
95%
95%
95%
A ()
1,4
0,82,3
1,1
0,81,5
1,4
1,01,9
1,2
0,91,7
1,4
0,92,0
1,3
0,91,8
1,3
0,81,9
HER2+, +, +
2,1
1,14,1
2,3
1,43,7
2,0
1,33,3
0,9
0,61,5
1,1
0,61,9
1,3
0,82,0
0,8
0,41,5
HER2+, ,
5,3
3,09,2
1,7
1,12,6
3,2
2,15,0
0,9
0,61,3
1,5
0,92,5
1,1
0,71,7
1,1
0,62,0
3,6
2,16,4
0,5
0,30,9
2,5
1,63,9
0,4
0,20,6
2,9
1,84,5
1,0
0,61,6
2,0
1,23,3
3,6
1,96,9
1,0
0,61,7
2,1
1,33,5
0,4
0,20,6
2,9
1,74,9
0,9
0,51,5
1,8
1,03,2
T34
0,2
0,10,4
0,5
0,30,8
1,4
1,11,9
0,7
0,61,0
2,3
1,83,1
2,1
1,62,9
1,5
1,22,0
2,2
1,63,1
2,2
1,63,0
1,5
1,02,3
> 50
0,5
0,40,7
0,6
0,50,8
. N, , , . N
, . ,
. .
: ; .
. HER2+
.35 ,
.
,
.
.
;
-
.
,
,
.
, .
,36,37 ,
- , 5 .36,38
, HER2+ . HER2
, HER2+ , 5 , 15
HER2+ .
15 .
( , , HER2)
6 % .18,39,40 10,9 7,2 %
.
1016 % HER2+ ,41,42
14,3 %, , , HER2+ (7,9 %).
HER2+ 2534 %,13,15,43,44 28,7 % HER2+ ,
15,4 % HER2+ . www.jco.org
HER2+ + HER2+ 13 .
- .2,16,23
:
, . ,7,10
, , . EGFR, -2 1 2.
,
, .9
.
, , ,
.7,14 , 50
, , ,
. (34)
, . , ,4
,
,
. , , ,
, .
American Society of Clinical Oncology
, , .45-47 HER2+
(28,7 %), (25,2 %)
(22 %)
. , ,
HER2+ .
Downloaded from jco.ascopubs.org on April 28, 2014. For personal use only. No other uses without permission.
Copyright 2010 American Society of Clinical Oncology. All rights reserved.
275
Kennecke et al.
, HER2+
HER2+ 30 %, . ,
.48
. , :
.49
,
HER2+ HER2+
RANK. ,
, .50 ,
, ,27,28,51
.
, .
,
,
, , .
12. Sotiriou C, Pusztai L: Gene-expression signatures in breast cancer. N Engl J Med 360:790800, 2009
13. Clayton AJ, Danson S, Jolly S, et al: Incidence of cerebral metastases in patients treated
with trastuzumab for metastatic breast cancer. Br
J Cancer 91:639-643, 2004
14. Dawood S, Broglio K, Esteva FJ, et al: Defining prognosis for women with breast cancer
and CNS metastases by HER2 status. Ann Oncol
19:1242-1248, 2008
15. Gaedcke J, Traub F, Milde S, et al: Predominance of the basal type and HER-2/neu type in brain
metastasis from breast cancer. Mod Pathol 20:864870, 2007
16. Hess KR, Pusztai L, Buzdar AU, et al: Estrogen receptors and distinct patterns of breast cancer
relapse. Breast Cancer Res Treat 78:105-118, 2003
17. Hicks DG, Short SM, Prescott NL, et al:
Breast cancers with brain metastases are more likely to be estrogen receptor negative, express the
basal cytokeratin CK5/6, and overexpress HER2 or
EGFR. Am J Surg Pathol 30:1097-1104, 2006
18. Lin NU, Bellon JR, Winer EP: CNS metastases in breast cancer. J Clin Oncol 22:3608-3617,
2004
19. Maki DD, Grossman RI: Patterns of disease
spread in metastatic breast carcinoma: Influence
of estrogen and progesterone receptor status. Am
J Neuroradiol 21:1064-1066, 2000
20. Slimane K, Andre F, Delaloge S, et al: Risk
factors for brain relapse in patients with metastatic
breast cancer. Ann Oncol 15:1640-1644, 2004
21. Tham YL, Sexton K, Kramer R, et al: Primary
breast cancer phenotypes associated with propensity for central nervous system metastases. Cancer
107:696-704, 2006
22. Weil RJ, Palmieri DC, Bronder JL, et al: Breast
cancer metastasis to the central nervous system.
Am J Pathol 167:913-920, 2005
23. Smid M, Wang Y, Zhang Y, et al: Subtypes
of breast cancer show preferential site of relapse.
Cancer Res 68:3108-3114, 2008
24. Perou CM, Sorlie T, Eisen MB, et al: Molecular portraits of human breast tumours. Nature
406:747-752, 2000
25. Parker JS, Mullins M, Cheang MC, et al: Supervised risk predictor of breast cancer based
on intrinsic subtypes. J Clin Oncol 27:1160-1167,
2009
26. Cheang MC, Voduc D, Bajdik C, et al: Basallike breast cancer defined by five biomarkers has
superior prognostic value than triple-negative phenotype. Clin Cancer Res 14:1368-1376, 2008
27. Nielsen TO, Hsu FD, Jensen K, et al: Immunohistochemical and clinical characterization of the
basal-like subtype of invasive breast carcinoma.
Clin Cancer Res 10:5367-5374, 2004
28. Cheang MC, Chia SK, Voduc D, et al: Ki67 index, HER2 status, and prognosis of patients with luminal B breast cancer. J Natl Cancer Inst 101:736750, 2009
29. Voduc D, Cheang M, Nielsen T: GATA-3 expression in breast cancer has a strong association
with estrogen receptor but lacks independent prognostic value. Cancer Epidemiol Biomarkers Prev
17:365-373, 2008
30. Cheang MC, Treaba DO, Speers CH, et al:
Immunohistochemical detection using the new rabbit monoclonal antibody SP1 of estrogen receptor in breast cancer is superior to mouse monoclonal antibody 1D5 in predicting survival. J Clin Oncol
24:5637-5644, 2006
31. Gray RJ: A class of K-sample tests for comparing the cumulative incidence of a competing
risk. Ann Stat 16:1141-1154, 1988
32. Pritchard KI, Shepherd LE, OMalley FP, et al:
HER2 and responsiveness of breast cancer to adjuvant chemotherapy. N Engl J Med 354:2103-2111,
2006
33. Romond EH, Perez EA, Bryant J, et al:
Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med
353:1673-1684, 2005
34. Piccart-Gebhart MJ, Procter M, LeylandJones B, et al: Trastuzumab after adjuvant che-
www.jco.org
tive factors and impact on overall survival. Ann Oncol 14:1072-1077, 2003
40. Dawood S, Broglio K, Esteva FJ, et al: Survival among women with triple receptor-negative
breast cancer and brain metastases. Ann Oncol
20:621-627, 2009
41. Gabos Z, Sinha R, Hanson J, et al: Prognostic significance of human epidermal growth factor
receptor positivity for the development of brain metastasis after newly diagnosed breast cancer. J Clin
Oncol 24:5658-5663, 2006
42. Saip P, Cicin I, Eralp Y, et al: Factors affecting
the prognosis of breast cancer patients with brain
metastases. Breast 17:451-458, 2008
43. Bendell JC, Domchek SM, Burstein HJ, et al:
Central nervous system metastases in women who
receive trastuzumab-based therapy for metastatic
breast carcinoma. Cancer 97:2972-2977, 2003
44. Altaha R, Crowell E, Ducatman B, et al: Risk
of brain metastases in HER2/neu-positive breast cancer. J Clin Oncol 22:47, 2004 (suppl 14; asbstr 682)
45. Recommended breast cancer surveillance
guidelines: American Society of Clinical Oncology.
J Clin Oncol 15:2149-2156, 1997
Downloaded from jco.ascopubs.org on April 28, 2014. For personal use only. No other uses without permission.
Copyright 2010 American Society of Clinical Oncology. All rights reserved.
277